A Study of Tanezumab in Adults With Chronic Low Back Pain

Phase 2

Completed

Conditions: Low Back Pain

Interventions: Biological: Tanezumab 20 mg IV
Biological: Tanezumab 10 mg IV
Biological: Tanezumab 5 mg IV
Biological: Placebo for tanezumab
Drug: Placebo for naproxen
Drug: Naproxen

Registration Number: NCT00876187

Lead Sponsor: Pfizer

Brief Summary: The purpose of this study is to evaluate the efficacy and safety of multiple doses of tanezumab administered every 8 weeks in treating chronic low back pain. Tanezumab is a monoclonal antibody directed against human nerve growth factor.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 1359

Inclusion Criteria

Present with duration of low back pain of ≥3 months requiring regular use of analgesic medication (>4 days per week for the past month). Analgesic medication may consist of NSAIDs, selective COX-2 inhibitors, immediate release opioids, or combinations, with certain protocol-defined limitations.
Primary location of low back pain must be between the 12th thoracic vertebra and the lower gluteal folds, with or without radiation into the posterior thigh
Must meet criteria for pain severity and global assessment of low back pain at Screening and Baseline visits
Female patients of child-bearing potential (and male patients with female partners who are of child-bearing potential) must use 2 methods of contraception throughout the study
Patients must be willing to discontinue all pain medications for chronic low back pain except rescue medication and not use prohibited pain medications throughout the duration of the study

Exclusion Criteria

History of lumbosacral radiculopathy within the past 2 years.
Back pain due to visceral disorder (eg, endometriosis).
Back pain due to major trauma or osteoporotic compression fracture in the past 6 months.
History of rheumatoid arthritis, seronegative spondyloarthropathy, Paget's disease of spine, pelvis or femur; fibromyalgia; tumors or infections of the spinal cord.
Surgical intervention during the past 6 months for the treatment of low back pain or plans for surgical intervention during the course of the study.
Current or pending worker's compensation, litigation, disability, or any other monetary settlement regarding his/her CLBP or any other pain condition, or any closed claim within the past 5 years.
Use of any analgesic or muscle relaxant within 48 hours prior to the five days before Baseline
Patients receiving only acetaminophen, gabapentin or pregabalin to manage their chronic low back pain.
Patients taking >325 mg/day of aspirin.
Use of any antidepressants with the exception of stable treatment with selective serotonin reuptake inhibitors (SSRIs).
Use of any sedatives/hypnotics, anxiolytics, tranquilizers, or benzodiazepines unless daily dose has been stable and will remain unchanged throughout the study period.
Systemic corticosteroid therapy within 30 days (inhaled and topical corticosteroids are permitted).
Local or epidural injection of corticosteroids, as well as injections of corticosteroids in the back within 3 months.
Botulinum toxin (Botox®) injection for chronic low back pain within 4 months.
Requirement for new, concomitant physiotherapy including, but not limited to, transdermal electroneural stimulation (TENS), massage or spinal manipulation for the duration of the study period.
Active or suspected esophageal, gastric, pyloric channel, or duodenal ulceration within 3 months, or any history of gastrointestinal bleeding.
Current use of lithium or anticoagulant agents.
Known hypersensitivity or intolerance to NSAIDs; history of asthma, urticaria, or allergic type reactions after taking aspirin or NSAIDs.
Inflammatory bowel disease, a chronic or acute renal or hepatic disorder, a significant coagulation defect, or other condition that might preclude the use of an NSAID.
History of intolerance to acetaminophen or paracetamol or any of its excipients.
History of known alcohol, analgesic or narcotic abuse within 2 years.
Presence of drugs of abuse (including prescription medications without a valid prescription), other illegal drugs or marijuana in the urine toxicology screen obtained at Screening.
History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal antibody or IgG fusion protein.
Use of biologics other than study medication, including any live vaccines, within 3 months, or use during the study (intranasal Flumist® vaccine is an exception).
Signs and symptoms of clinically significant cardiac disease.
Diagnosis of a transient ischemic attack within the 6 months, or residual deficits from stroke that would preclude completion of required study activities.
History of cancer within 5 years.
Use of any investigational medication within 30 days (3 months for investigational biologics).
Expected to undergo a therapeutic procedure or to use any analgesic other than those specified in the protocol throughout the study period.
Previous exposure to exogenous NGF or to an anti NGF antibody.
Screening laboratory results and blood pressure within specified limits.
Positive Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV) tests at screening.
History, diagnosis, or signs and symptoms of clinically significant neurological disease.
History, diagnosis, signs or symptoms of any clinically significant psychiatric disorder.
Hospital admission for depression or suicide attempt within 5 years or active, severe major depression at Screening.
Likelihood of being non compliant with study procedures.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Tanezumab 20 mg IV	Tanezumab 20 mg IV	-
Tanezumab 20 mg IV	Placebo for naproxen	-
Tanezumab 10 mg IV	Tanezumab 10 mg IV	-
Tanezumab 5 mg IV	Tanezumab 5 mg IV	-
Naproxen	Placebo for tanezumab	-
Naproxen	Naproxen	-
Placebo	Placebo for tanezumab	-
Placebo	Placebo for naproxen	-
Tanezumab 10 mg IV	Placebo for naproxen	-
Tanezumab 5 mg IV	Placebo for naproxen	-

Primary Outcome Measures

Name	Time	Method
Change From Baseline in Daily Average Low Back Pain Intensity (LBPI) Score at Week 16: Baseline Observation Carried Forward (BOCF)	Baseline, Week 16	Daily average back pain was assessed on an 11-point numeric rating scale (NRS) captured through an interactive voice response system (IVRS). The participant described the chronic low back pain (CLBP) during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline value was calculated as mean of the scores over 5 days prior to randomization (initial pain assessment period). Post-baseline value was calculated as mean of the scores over the 7-day period prior to and including the post-baseline visit. Overall possible score range for daily average LBPI at specified visit was 0= no pain to 10= worst possible pain, where higher scores indicated higher pain intensity.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in Patient's Global Assessment (PGA) of Low Back Pain Score at Week 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF)	Baseline, Week 2, 4, 8, 12, 16	Participants answered: "Considering all ways your low back pain affects you, how are you doing today?" Participants rated their condition using scale assessing symptoms and limitations to carry out normal daily activities. Score range:1 to 5. 1: Very Good (No symptoms and limitations); 2: Good (Mild symptoms and no limitations); 3: Fair (Moderate symptoms and some limitations); 4: Poor (Severe symptoms and inability to carry out most activities); 5: Very Poor (Very severe, intolerable symptoms and inability to carry all activities).
Percentage of Participants With at Least 30 Percent (%) and 50% Reduction From Baseline in Daily Average Low Back Pain Intensity (LBPI) Score at Week 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF)	Baseline, Week 2, 4, 8, 12, 16	Daily average back pain was assessed on an 11-point numeric rating scale (NRS) captured through an interactive voice response system (IVRS). The participant described the chronic low back pain (CLBP) during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline value was calculated as mean of the scores over 5 days prior to randomization (initial pain assessment period). Post-baseline value was calculated as mean of the scores over the 7-day period prior to and including the post-baseline visit.
Change From Baseline in Brief Pain Inventory-short Form (BPI-sf) Score for Pain Interference Index, Pain Interference Score for General Activity, Walking Ability, Sleep and Normal Work at Week 2, 4, 8, 12 and 16: BOCF	Baseline, Week 2, 4, 8, 12, 16	BPI-sf: self-report questionnaire rated on an 11-point scale, consists of 5 questions to assess severity and impact of pain on daily functions. Question 1-4 (Q1-Q4) measure severity of pain (worst, least, average, right now), each question ranging between 0 (no pain) to 10 (pain as bad as you can imagine). Question 5 (Q5) consists of 7 items which measure pain interference (PI) on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life), each item ranging from 0 (does not interfere) to 10 (completely interferes); higher score = greater impairment. The 7 items in Q5 averaged to obtain pain interference index (function composite score), range: 0 (no interference) to 10 (complete interference); higher score = greater impairment.
Number of Participants With Chronic Low Back Pain (CLBP) Responder Index: Baseline Observation Carried Forward (BOCF)	Week 2, 4, 8, 12, 16	Chronic Low Back Pain (CLBP) Responder Index: A response was defined as reduction of at least 30% in mean daily average LBPI from baseline to a specified week, decrease of at least 30% in PGA of low back pain from baseline to the specified week and no worsening (increase) in RMDQ total score from baseline to the specified week. Participants who were responders were reported.
Duration of Rescue Medication Use	Week 2, 4, 8, 12, 16	In case of inadequate pain relief for CLBP or for non-CLBP related pain, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication.
Amount of Rescue Medication Taken	Week 2, 4, 8, 12, 16	In case of inadequate pain relief for CLBP or for non-CLBP related pain, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication.
Change From Baseline in Brief Pain Inventory-short Form (BPI-sf) Score for Worst and Average Pain at Week 2, 4, 8, 12, 16: Baseline Observation Carried Forward (BOCF)	Baseline, Week 2, 4, 8, 12, 16	BPI-sf: self-report questionnaire rated on an 11-point scale, consists of 5 questions to assess severity and impact of pain on daily functions. Question 1-4 (Q1-Q4) measure severity of pain (worst, least, average, right now), each question ranging between 0 (no pain) to 10 (pain as bad as you can imagine). Question 5 (Q5) consists of 7 items which measure level of interference of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life), each item ranging from 0 (does not interfere) to 10 (completely interferes). Results are reported for worst and average pain, each with a score range: 0 (no pain) and 10 (pain as bad as you can imagine), higher scores indicated worse pain.
Total Nerve Growth Factor (NGF) Concentration	Baseline (pre-dose and 1 hour [hr] post-dose); Any time point at Week 4 Visit; Week 8 (pre-dose and 1 hr post-dose); Any time point at Week 16 Visit, at Week 24 Visit
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	Baseline up to Week 24	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 24 that were absent before treatment or that worsened relative to pretreatment state. AEs included SAEs as well as non-serious AEs which occurred during the trial.
Number of Participants With Cumulative Reduction From Baseline at Week 16 in Daily Average Low Back Pain Intensity (LBPI) Score : Baseline Observation Carried Forward (BOCF)	Baseline, Week 16	Daily average back pain was assessed on an 11-point numeric rating scale (NRS) captured through an interactive voice response system (IVRS). The participant described the chronic low back pain (CLBP) during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline value was calculated as mean of the scores over 5 days prior to randomization (initial pain assessment period). Post-baseline value was calculated as mean of the scores over the 7-day period prior to and including the post-baseline visit. Participants with specified reduction (as percent) from baseline at Week 16 are reported.
Time to Discontinuation Due to Lack of Efficacy	Baseline up to Week 16	Median time to discontinuation due to lack of efficacy was estimated using Kaplan-Meier method.
Change From Baseline in Roland-Morris Disability Questionnaire (RMDQ) Total Score at Week 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF)	Baseline, Week 2, 4, 8, 12, 16	RMDQ: back-specific, participant administered questionnaire that assesses how well participants with low back pain were able to function with regard to daily activities. The questionnaire consists of 24 statements and the participant is instructed to put a mark next to each appropriate statement if it describes his/her functional ability on the day of assessment. The number of statements marked are added up by the clinician. Total RMDQ score is calculated as the sum of number of statements marked. Total possible RMDQ score: 0 (best functioning) to 24 (worst functioning), with higher scores indicated greater disability.
Change From Baseline in Daily Average Low Back Pain Intensity (LBPI) Score at Week 2, 4, 8 and 12: Baseline Observation Carried Forward (BOCF)	Baseline, Week 2, 4, 8, 12	Daily average back pain was assessed on an 11-point numeric rating scale (NRS) captured through an interactive voice response system (IVRS). The participant described the chronic low back pain (CLBP) during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline value was calculated as mean of the scores over 5 days prior to randomization (initial pain assessment period). Post-baseline value was calculated as mean of the scores over the 7-day period prior to and including the post-baseline visit.
Change From Baseline in Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) at Week 8 and 16	Baseline, Week 8, 16	WPAI:SHP is a self-administered questionnaire that measures the effect of general health and symptom severity on work productivity and regular activities. Four scores are derived as percent: activity impairment (AI), impairment while working (IW), overall work impairment (OWI), work time missed (WTM). Each of 4 scores expressed as impairment percentages with a total possible score range of 0 to 100, high percentage= more impairment, less productivity.
Percentage of Participants Who Used Rescue Medications	Week 2, 4, 8, 12, 16	In case of inadequate pain relief for CLBP or for non-CLBP related pain, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication.
Change From Baseline Neuropathy Impairment Score (NIS) at Week 8, 16 and 24	Baseline, Week 8, 16, 24	NIS is a standardized instrument used to evaluate signs of peripheral neuropathy in participants. NIS is the sum of scores of 37 items, from both the left and right side of following 4 domains: cranial nerves (5 items), muscle weakness (19 items), reflexes (5 items) and sensation (8 items). Each of 24 items related to cranial nerves and muscle weakness, scored from 0 (normal) to 4 (paralysis); higher scores indicated higher abnormality/impairment. Each of 13 items related to reflexes and sensation, scored as 0 (normal), 1 (decreased) and 2 (absent); higher scores indicated lesser reflexes and sensation. For NIS possible overall score (combined of both left and right sides of each domain), ranged from 0 (no impairment) to 244 (maximum impairment), higher scores indicated increased/more neuropathic deficits.
Number of Participants Who Developed Anti-Tanezumab Antibodies	Baseline (Day 1), Week 8, 16, 24	Human serum anti-drug antibody (ADA) samples were analyzed for the presence or absence of anti-tanezumab antibodies by using the semi-quantitative enzyme-linked immunosorbent assay (ELISA). Same participant may have positive ADA result at more than 1 time point.
Plasma Concentration of Tanezumab	Baseline (pre-dose and 1 hour [hr] post-dose); Any time point at Week 4 Visit; Week 8 (pre-dose and 1 hr post-dose); Any time point at Week 16 Visit, at Week 24 Visit	Analysis was done by setting concentration values below the lower limit of quantification (LLOQ) to zero.

Trial Locations

Locations (129): Comprehensive Clinical Research
🇺🇸
Berlin, New Jersey, United States
Advances In Health, Inc.
🇺🇸
Houston, Texas, United States
Clinical Research Consortium
🇺🇸
Las Vegas, Nevada, United States
Mirkil Medical
🇺🇸
Las Vegas, Nevada, United States
Office of Theresia Lee, MD
🇺🇸
San Antonio, Texas, United States
Paragon Research Center
🇺🇸
San Antonio, Texas, United States
Progressive Clinical Research, PA
🇺🇸
San Antonio, Texas, United States
Clinical Trials Technology, Inc.
🇺🇸
Prairie Village, Kansas, United States
Vince and Associates Clinical Research
🇺🇸
Overland Park, Kansas, United States
Cotton-O'Neil Clinical Research
🇺🇸
Topeka, Kansas, United States
Christine Codding, MD
🇺🇸
Oklahoma City, Oklahoma, United States
Health Research of Oklahoma
🇺🇸
Oklahoma City, Oklahoma, United States
Radiant Research, Inc.: Scottsdale, AZ
🇺🇸
Scottsdale, Arizona, United States
Clinical Research Advantage, Inc./Fiel Family and Sports Medicine, PC
🇺🇸
Tempe, Arizona, United States
Providence Clinical Research
🇺🇸
Burbank, California, United States
Premiere Phamaceutical Research, LLC
🇺🇸
Tempe, Arizona, United States
Pinnacle Research Group, LLC
🇺🇸
Anniston, Alabama, United States
University of California San Diego
🇺🇸
La Jolla, California, United States
Valley Research
🇺🇸
Fresno, California, United States
Samaritan Center for Medical Research Medical Group
🇺🇸
Los Gatos, California, United States
Arizona Research Center
🇺🇸
Phoenix, Arizona, United States
Little Rock Family Practice Clinic
🇺🇸
Little Rock, Arkansas, United States
Collaborative Neuroscience Network, Inc
🇺🇸
Garden Grove, California, United States
Stamford Therapeutics Consortium
🇺🇸
Stamford, Connecticut, United States
Clinicos, LLC
🇺🇸
Colorado Springs, Colorado, United States
Wetlin Research Associates, Inc
🇺🇸
San Diego, California, United States
Elite Clinical Trials
🇺🇸
Wildomar, California, United States
Southeast Clinical Research, LLC
🇺🇸
Jacksonville, Florida, United States
Alpine Clinical Research Center
🇺🇸
Boulder, Colorado, United States
New England Research Associates, LLC
🇺🇸
Trumbull, Connecticut, United States
Meridien Research
🇺🇸
Saint Petersburg, Florida, United States
CRIA Research
🇺🇸
Fort Lauderdale, Florida, United States
Pharmquest
🇺🇸
Greensboro, North Carolina, United States
Rochester Clinical Research
🇺🇸
Rochester, New York, United States
Wake Research Associates, LLC
🇺🇸
Raleigh, North Carolina, United States
Central New York Clinical Research
🇺🇸
Manlius, New York, United States
Medex Healthcare Research
🇺🇸
New York, New York, United States
Rapid Medical Research, Inc.
🇺🇸
Cleveland, Ohio, United States
Community Research
🇺🇸
Cincinnati, Ohio, United States
Radiant Research
🇺🇸
Greer, South Carolina, United States
Columbia Arthritis Center, P.A.
🇺🇸
Columbia, South Carolina, United States
Centex Research
🇺🇸
Nassau Bay, Texas, United States
Centex Research, Inc.
🇺🇸
Houston, Texas, United States
KRK Medical Research
🇺🇸
Dallas, Texas, United States
Advanced Pain Management
🇺🇸
Virginia Beach, Virginia, United States
Simon Williamson Clinic, PC
🇺🇸
Birmingham, Alabama, United States
Saadat Ansari, MD office
🇺🇸
Huntsville, Alabama, United States
Quality Clinical Research, Inc.
🇺🇸
Omaha, Nebraska, United States
Meridian Clinical Research, LLC
🇺🇸
Omaha, Nebraska, United States
Summit Research Network (Oregon), Inc.
🇺🇸
Portland, Oregon, United States
Advanced Therapeutics, Inc.
🇺🇸
Johnson City, Tennessee, United States
Collier Neurologic Specialists
🇺🇸
Naples, Florida, United States
Northstate Clinical Research, PLLC
🇺🇸
Lenoir, North Carolina, United States
Radiant Research - Phoenix Southeast
🇺🇸
Chandler, Arizona, United States
Pinnacle Research Group LLC
🇺🇸
Anniston, Alabama, United States
Simon-Williamson Clinic, PC
🇺🇸
Hueytown, Alabama, United States
Horizon Research Group
🇺🇸
Mobile, Alabama, United States
Pivotal Research Centers
🇺🇸
Peoria, Arizona, United States
Alta Clinical Research, LLC
🇺🇸
Tucson, Arizona, United States
Advances in Medicine
🇺🇸
Rancho Mirage, California, United States
North County Clinical Research (NCCR)
🇺🇸
Oceanside, California, United States
Inland Rheumatology & Osteoporosis Medical Group, Inc.
🇺🇸
Upland, California, United States
Doctors Medical Center of Walton County
🇺🇸
DeFuniak Springs, Florida, United States
Jacksonville Center for Clinical Research
🇺🇸
Jacksonville, Florida, United States
Avail Clinical Research, LLC
🇺🇸
DeLand, Florida, United States
SJS Clinical Research, Inc.
🇺🇸
Destin, Florida, United States
University Clinical Research Incorporated
🇺🇸
Pembroke Pines, Florida, United States
Advent Clinical Research Center
🇺🇸
Pinellas Park, Florida, United States
Dale G. Bramlet, MD
🇺🇸
Saint Petersburg, Florida, United States
Arthntis & Rheumatic Care Center
🇺🇸
South Miami, Florida, United States
Miami Research Associates
🇺🇸
South Miami, Florida, United States
Palm Beach Research Center
🇺🇸
West Palm Beach, Florida, United States
Center for Prospective Outcome Studies
🇺🇸
Atlanta, Georgia, United States
River Birch Research Alliance, LLC
🇺🇸
Blue Ridge, Georgia, United States
Drug Studies America
🇺🇸
Marietta, Georgia, United States
Selah Medical Center, PA
🇺🇸
Boise, Idaho, United States
MediSphere Medical Research Center, LLC
🇺🇸
Evansville, Indiana, United States
Commonwealth Biomedical Research, LLC
🇺🇸
Madisonville, Kentucky, United States
Arthritis and Diabetes Clinic
🇺🇸
Monroe, Louisiana, United States
Peter A. Holt, MD
🇺🇸
Baltimore, Maryland, United States
PCM Medical Services
🇺🇸
Lansing, Michigan, United States
Clinical Research Center of Jackson
🇺🇸
Jackson, Mississippi, United States
The Center for Clinical Trials
🇺🇸
Biloxi, Mississippi, United States
Physician's Surgery Center
🇺🇸
Jackson, Mississippi, United States
Medex Healthcare Research, Inc.
🇺🇸
New York, New York, United States
Clinvest/ A Division of Banyan Group, Inc.
🇺🇸
Springfield, Missouri, United States
Mercy Health Research
🇺🇸
Saint Louis, Missouri, United States
Advanced Biomedical Research of America
🇺🇸
Las Vegas, Nevada, United States
CRI Worldwide
🇺🇸
Willingboro, New Jersey, United States
Finger Lakes Clinical Research
🇺🇸
Rochester, New York, United States
Upstate Clinical Research Associates
🇺🇸
Williamsville, New York, United States
The Medical Research Network, LLC
🇺🇸
New York, New York, United States
Wake Internal Medicine Consultants, Inc.
🇺🇸
Raleigh, North Carolina, United States
Sterling Research
🇺🇸
Cincinnati, Ohio, United States
Sunstone Medical Research, LLC
🇺🇸
Medford, Oregon, United States
CRI Worldwide LLC
🇺🇸
Philadelphia, Pennsylvania, United States
McBride Clinic
🇺🇸
Oklahoma City, Oklahoma, United States
Altoona Center for Clinical Research
🇺🇸
Duncansville, Pennsylvania, United States
Lynn Health Science Institute
🇺🇸
Oklahoma City, Oklahoma, United States
Allegheny Pain Management
🇺🇸
Altoona, Pennsylvania, United States
Paramount Clinical Research
🇺🇸
Bridgeville, Pennsylvania, United States
New England Center for Clinical Research
🇺🇸
Cranston, Rhode Island, United States
SCRI Research Center
🇺🇸
Germantown, Tennessee, United States
Omega Medical Research
🇺🇸
Warwick, Rhode Island, United States
Health Concepts
🇺🇸
Rapid City, South Dakota, United States
Wolf River Medical Group, LLC
🇺🇸
Germantown, Tennessee, United States
Johnson City Internal Medicine
🇺🇸
Johnson City, Tennessee, United States
DiscoveResearch, Inc.
🇺🇸
Beaumont, Texas, United States
DiscoveResearch, Incorporated
🇺🇸
Bryan, Texas, United States
Trinity Hypertension & Metabolic Research Institute Punzi Medical Center
🇺🇸
Carrollton, Texas, United States
Charlottesville Medical Research
🇺🇸
Charlottesville, Virginia, United States
Foothill Family Clinic
🇺🇸
Salt Lake City, Utah, United States
National Clinical Research - Norfolk, Inc.
🇺🇸
Norfolk, Virginia, United States
Northwest Clinical Research Center
🇺🇸
Bellevue, Washington, United States
Clinical Pharmacology Study Group
🇺🇸
Worcester, Massachusetts, United States
Quality Control Research, Inc
🇺🇸
Roseville, California, United States
Southern Orthopaedic Sports Medicine
🇺🇸
Columbia, South Carolina, United States
East Penn Rheumatology Associates, PC
🇺🇸
Bethlehem, Pennsylvania, United States
Center for Clinical Trials of Sacramento, Inc.
🇺🇸
Sacramento, California, United States
Compass Research, LLC
🇺🇸
Orlando, Florida, United States
The Center for Clinical Research
🇺🇸
Winston-Salem, North Carolina, United States
Capitol Medical Clinic
🇺🇸
Austin, Texas, United States
Walter F. Chase, MD, PA
🇺🇸
Austin, Texas, United States
FutureSearch Trials of Neurology
🇺🇸
Austin, Texas, United States
FutureSearch Trials
🇺🇸
Austin, Texas, United States
National Clinical Research, Incorporated
🇺🇸
Richmond, Virginia, United States
Central Kentucky Research Association, Inc.
🇺🇸
Lexington, Kentucky, United States
Albuquerque Clinical Trials
🇺🇸
Albuquerque, New Mexico, United States
Southeast Clinical Research
🇺🇸
Chiefland, Florida, United States